Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination
Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination
Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination
Submitted by
admin
on September 6, 2018 - 9:35am
Source:
CP Wire
News Tags:
Vertex Pharmaceuticals
VX-659
VX-445
correctors
cystic fibrosis
Headline:
Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination
snippet:
VX-659 and VX-445 are next gen correctors
Correctors fix the defective CFTR protein so that it can move to the proper place on the cell surface
Vertex expects to submit an NDA for one of the drugs no later than mid-2019
Do Not Allow Advertisers to Use My Personal information
